INVESTORS

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

 

About Us

HT-002

WHAT IS HT-002?

HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.

Development Status

HT-002 is at the preclinical stage of development.

In June 2020, Hoth entered a research agreement with Virginia Commonwealth University (“VCU”) to develop and optimize the novel peptide therapeutic. Preclinical results are expected in Q1 2021.

EXTERNAL RESOURCES